Publications & Posters
Scholary publications
Spinal Muscular Atrophy
Apitegromab
March 2022
2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Apitegromab in SMA: An Analysis of PK/PD Relationships to Efficacy in Ambulatory Patients from the TOPAZ Trial (#72)
Immuno-Oncology
SRK-181
January 2022
2nd Annual TGFβ for Immuno-Oncology Drug Development Summit
Development of a Comprehensive Biomarker Strategy to Support DRAGON, a Phase 1 Clinical Trial of SRK-181, the latent TGFβ1 Inhibitor (Presentation)
Immuno-Oncology
SRK-181
November 2021
36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
First-in-Human Phase 1 Trial of SRK-181: A Latent TGFβ1 inhibitor, Alone or in Combination with Anti-PD-(L)1 Treatment in Patients with Advanced Solid Tumors (DRAGON trial) (#532)
Spinal Muscular Atrophy
Apitegromab
October 2021
2021 World Congress of Neurology (WCN)
Relationship of Pharmacokinetics and Pharmacodynamics to Apitegromab Efficacy in Patients with Later-onset Spinal Muscular Atrophy (Types 2 and 3 SMA): Results from the TOPAZ Study (Poster #EP1150)
Spinal Muscular Atrophy
Apitegromab
September 2021
2021 Child Neurology Society (CNS) Annual Meeting
Efficacy of Apitegromab in Patients with Later-Onset Spinal Muscular Atrophy (SMA Types 2 and 3): Responder Analysis from the Phase 2 TOPAZ Study (#310)
Spinal Muscular Atrophy
Apitegromab
September 2021
World Muscle Society 2021 Virtual Congress
